Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

482.69 +7.50 (+1.58%)
Streaming Delayed Price Updated: 12:37 PM EDT, Jun 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
66 67 Next >
News headline image
The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch. ↗
The iShares Nasdaq Biotechnology ETF (IBB) is trading just 1.47% below its 52-week high, signaling a potential multi-year sector breakout. 
Via MarketBeat
Topics ETFs
Vertex Pharmaceuticals (NASDAQ:VRTX): A GARP Growth Stock with Reasonable Valuation and Strong Fundamentals ↗
Via Chartmill
News headline image
The Best Stocks to Invest $1,000 in Right Now ↗
Exploring some of the top bargains in a multi-trillion-dollar industry. 
Via The Motley Fool
News headline image
3 of Wall Street’s Favorite Stocks to Consider Right Now
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f... 
Via StockStory
VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX): Affordable Growth with Strong Fundamentals ↗
Via Chartmill
Vertex Pharmaceuticals (NASDAQ:VRTX): Strong Growth Meets a Technical Setup for a Potential Breakout ↗
Via Chartmill
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Fits the Affordable Growth Profile With Strong Earnings and Reasonable Valuation ↗
Via Chartmill
Vertex Pharmaceuticals (NASDAQ:VRTX) Beats Q1 Estimates as New Drug Launches Drive Diversification ↗
Via Chartmill
News headline image
2 Reasons to Like VRTX (and 1 Not So Much)
Vertex Pharmaceuticals has been treading water for the past six months, recording a small loss of 1.6% while holding steady at $452.99. The stock also fell s... 
Via StockStory
News headline image
If I Had to Start Over With $1,000 in Stocks Today, Here's Exactly What I'd Buy ↗
These well-established companies are on track to deliver more growth. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Vertex Has a Head Start in Non-Opioid Pain. Eli Lilly Just Spent Billions to Catch Up. Here's What That Means for Both Stocks. ↗
These companies don't typically compete directly with one another, but that might change soon. 
Via The Motley Fool
News headline image
Why CRISPR Therapeutics Stock Has Been on a Roller-Coaster Ride This Year ↗
The opportunity is enormous, but uncertainty remains. 
Via The Motley Fool
News headline image
3 Market-Beating Stocks Worth Investigating
Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three ... 
Via StockStory
News headline image
The Best Biotech Stocks to Buy in 2026 ↗
They have at least one thing in common: An exciting pipeline. 
Via The Motley Fool
Topics ETFs
News headline image
Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026? ↗
A clinical-stage innovator faces off against an established biotech powerhouse, each with distinct financials and risk profiles shaping their 2026 outlook. 
Via The Motley Fool
News headline image
CRISPR Therapeutics Has $2.4 Billion in Cash and an Approved Drug. Why Is Its Stock Trading Nearly 40% Below the Wall Street Consensus? ↗
The company seems to be doing everything it's supposed to be doing; the stock just isn't responding. 
Via The Motley Fool
News headline image
The Best Stocks to Invest $500 in Right Now ↗
The market is underestimating these companies' long-term prospects. 
Via The Motley Fool
News headline image
2 Healthcare Stocks with Exciting Potential and 1 Facing Challenges
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But financial performance has lagged recently as players offloade... 
Via StockStory
News headline image
Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics? ↗
Are there significant gains ahead for one (or both) of these innovative biotechs? 
Via The Motley Fool
Which S&P500 stocks are moving on Tuesday? ↗
Via Chartmill
News headline image
1 Top Wall Street Analyst Thinks CRISPR Therapeutics Could More Than Double. Should You Buy the Stock Hand Over Fist? ↗
The biotech's innovative platform could pay off. 
Via The Motley Fool
News headline image
5 Must-Read Analyst Questions From Vertex Pharmaceuticals’s Q1 Earnings Call
Vertex Pharmaceuticals' first quarter results reflected balanced growth across its cystic fibrosis franchise and newly launched therapies, with management hi... 
Via StockStory
Topics Earnings
News headline image
Is This Millionaire-Maker Biotech Stock a Buy Right Now? ↗
The market wasn't impressed by its latest quarterly update. 
Via The Motley Fool
Topics Initial Public Offering
News headline image
Vertex (VRTX) Q1 2026 Earnings Call Transcript ↗
Vertex (VRTX) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Vertex Pharmaceuticals Reports Mixed Q1 Results ↗
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) reports financial results for the first quarter after the market close on Monday. 
Via Benzinga
News headline image
Vertex Pharmaceuticals (NASDAQ:VRTX) Beats Q1 CY2026 Sales Expectations
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) beat Wall Street’s revenue expectations in Q1 CY2026, with sales up 7.8% year on year to $2.99 billion. ... 
Via StockStory
News headline image
Vertex (VRTX) Q2 2025 Earnings Call Transcript ↗
Vertex (VRTX) Q2 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Vertex Pharmaceuticals (VRTX) Q1 Earnings: What To Expect
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results this Monday after the bell. Here’s what investors should know. Vertex Pharmace... 
Via StockStory
News headline image
Got $1,000? Which of These Beaten-Down Healthcare Stocks Is Worth Buying? ↗
These longtime market beaters may not have peaked yet. 
Via The Motley Fool
Topics World Trade
News headline image
Set It and Forget It: 3 Monster Stocks Worth Holding Through Whatever Comes Next ↗
They may suffer the occasional knee-jerk setback. By and large, though, investors understand these companies are capable of standing up to almost any challenge. 
Via The Motley Fool
Topics Credit Cards Economy
< Previous 1 2 3 4 5 6 7 8 9
...
66 67 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.